Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
AUTOR(ES)
Zinman, Bernard
FONTE
American Diabetes Association
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2699702Documentos Relacionados
- Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
- Glucagon-like peptide-1 is a physiological incretin in rat.
- The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
- Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
- Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats